Led by CuriRx’s team of industry experts and state-of-the-art
high-resolution Orbitrap mass spectrometry instrumentation,
our one-of-a-kind CuriLytics™ platform provides support
to developers of complex biotherapeutics.

Improving and de-risking the overall drug development path from Phase I clinical trials through approval requires advanced analyses of critical quality attributes. Modern biopharmaceutical drugs, such as recombinant proteins, monoclonal antibodies (mAb), bispecific antibodies, vaccines, antibody drug conjugates (ADCs), oligonucleotides, and gene therapy (AAV’s) are very complex molecules. Characterizing these molecules can present a significant challenge.

By using high-resolution mass spectrometry and a battery of orthogonal characterization methods, CuriLytics™ offers a powerful way to overcome these challenges, providing greater insight in characterization and improved understanding of biotherapeutic drugs. CuriLytics™ identifies quality attributes of protein candidates at the individual residue level, offering a detailed understanding of how changes in process or production affect a drug product.